PRESCIENT THERAPEUTICS LIMITED 26 November 2015
The Company Announcements Platform ASX Limited
By E-lodgement
Professor Farhad Ravandi MD is based at the MD Anderson and Moffitt Cancer Center, which is one of the world's most prestigious cancer institutions.
He currently holds position as Professor and Chief, Section of Developmental Therapeutics within the Department of Leukemia, Division of Cancer Medicine at the Texas facility.
His PTX appointment is especially significant ahead of the Company's upcoming clinical trial in Acute Myeloid Leukaemia (AML) in early 2016.
Professor Ravandi is actively involved in clinical and translational research for the treatment of patients with various hematological malignancies, with a particular focus on leukaemias.
He has extensively published his clinical research results in the field of adult leukaemias, with a specific interest in acute leukaemias.
The University of Texas MD Anderson Cancer Center, located in Houston, is one of the world's largest and most respected centres devoted exclusively to cancer patient care, research, education and prevention.
Professor Ravandi was an investigator on PTX's Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Centre in 32 patients with advanced hematologic malignancies.
The study showed that 17 out of 32 patients had stable disease after one cycle of treatment and 3 patients with AML had >50% bone marrow blast reduction.
Professor Ravandi said, 'The Phase 1 AML study had encouraging results demonstrating that further investigation of PTX-200 alone, or in combination, in patients with high AKT levels is warranted.'
'I am delighted to join the Company's SAB, particularly on the eve of PTX commencing a new AML clinical study at Moffitt in early 2016. PTX-200 has the potential to change patient's lives in this difficult to treat disease.'
PTX Executive Director Mr Paul Hopper said, 'We are honored to have someone of Professor Ravandi's calibre joining our SAB. He is recognised as a leading international authority in AML and his hands-on experience with our drug will be invaluable as we drive development of PTX-200 in our upcoming Phase 1b/2 trial.'
Prescient Therapeutics Limited
Level 4, 100 Albert Road, South Melbourne, VIC 3205
Phone: +61 3 9692 7222 Fax: +61 3 9077 9233
ABN: 56 006 569 106 ACN: 006 569 106
www.prescienttherapeutics.com
ASX ANNOUNCEMENT
PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.
Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's H. Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia.
PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.
Further Inquiries: Steven Engle | Paul Hopper | Rudi Michelson |
Chairman +1 858 922 7768 (US) | Executive Director +61 406 671 515 | Monsoon Communications +61 3 9620 3333 |
|
distributed by
|
